Background: The use of CCR5 antagonists involves determination of HIV-1 tropism prior to initiation of treatment. HIV-1 tropism can be assessed either by phenotypic or genotypic methods. Genotypic methods are extensively used for tropism prediction. However, their validation in predicting tropism of viral isolates belonging to group M non-B subtypes remains challenging. In Cameroon, the genetic diversity of HIV-1 strains is the broadest reported worldwide. To facilitate the integration of CCR5 antagonists into clinical practice in this region, there is a need to evaluate the performance of genotypic methods for predicting tropism of highly diverse group M HIV-1 strains. Methods: Tropism of diverse HIV-1 strains isolated from PBMCs from Came...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...
Objectives: Although founder viruses in primary HIV-1 infections (PHIs) typically use the CCR5 corec...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...
The use of CCR5 antagonists involves determination of HIV-1 tropism prior to initiation of treatment...
International audienceObjectivesThere is no consensus about the performances of genotypic rules for ...
Genotypic tropism testing (GTT) has been developed largely on HIV-1 subtype B. Although a few report...
It remains unknown whether the C-C motif chemokine receptor type 5 (CCR5) coreceptor is still the pr...
International audienceUNLABELLED: ABSTRACT: BACKGROUND: HIV-1 subtype D infections have been associa...
Abstract Background HIV-1 subtype D infections have been associated with rapid disease progression a...
Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infecte...
Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infecte...
Objective. The use of CCR5 inhibitors requires a tool to predict human immunodeficiency virus type 2...
Objectives: HIV-1 tropism needs to be determined before the use of CCR5 antagonist drugs such as mar...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...
Objectives: Although founder viruses in primary HIV-1 infections (PHIs) typically use the CCR5 corec...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...
The use of CCR5 antagonists involves determination of HIV-1 tropism prior to initiation of treatment...
International audienceObjectivesThere is no consensus about the performances of genotypic rules for ...
Genotypic tropism testing (GTT) has been developed largely on HIV-1 subtype B. Although a few report...
It remains unknown whether the C-C motif chemokine receptor type 5 (CCR5) coreceptor is still the pr...
International audienceUNLABELLED: ABSTRACT: BACKGROUND: HIV-1 subtype D infections have been associa...
Abstract Background HIV-1 subtype D infections have been associated with rapid disease progression a...
Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infecte...
Over the past decade antiretroviral drugs have dramatically improved the prognosis for HIV-1 infecte...
Objective. The use of CCR5 inhibitors requires a tool to predict human immunodeficiency virus type 2...
Objectives: HIV-1 tropism needs to be determined before the use of CCR5 antagonist drugs such as mar...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...
Objectives: Although founder viruses in primary HIV-1 infections (PHIs) typically use the CCR5 corec...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...